PLN 9.19
(-3.26%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -11.19 PLN | 5.73% |
2022 | -11.87 PLN | -101.87% |
2021 | -5.88 PLN | 19.67% |
2020 | -7.32 PLN | -136.89% |
2019 | -3.09 PLN | -423.73% |
2018 | -0.59 PLN | 23.38% |
2017 | -0.77 PLN | 4.94% |
2016 | -0.81 PLN | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.90 PLN | 39.6% |
2024 Q1 | -1.49 PLN | 57.31% |
2023 Q3 | -2.36 PLN | 23.38% |
2023 Q4 | -3.49 PLN | -47.88% |
2023 Q1 | -2.53 PLN | 18.65% |
2023 Q2 | -3.08 PLN | -21.74% |
2023 FY | - PLN | 5.73% |
2022 Q2 | -2.57 PLN | 20.43% |
2022 Q4 | -3.11 PLN | -7.99% |
2022 FY | - PLN | -101.87% |
2022 Q1 | -3.23 PLN | -941.94% |
2022 Q3 | -2.88 PLN | -12.06% |
2021 Q1 | -1.48 PLN | 28.16% |
2021 FY | - PLN | 19.67% |
2021 Q3 | -1.93 PLN | -11.56% |
2021 Q4 | -0.31 PLN | 83.94% |
2021 Q2 | -1.73 PLN | -16.89% |
2020 Q4 | -2.06 PLN | -28.75% |
2020 FY | - PLN | -136.89% |
2020 Q2 | -2.04 PLN | -110.31% |
2020 Q3 | -1.60 PLN | 21.57% |
2020 Q1 | -0.97 PLN | 20.49% |
2019 Q2 | -0.74 PLN | -146.67% |
2019 Q1 | -0.30 PLN | -30.43% |
2019 FY | - PLN | -423.73% |
2019 Q4 | -1.22 PLN | -114.04% |
2019 Q3 | -0.57 PLN | 22.97% |
2018 Q3 | -0.21 PLN | 0.0% |
2018 FY | - PLN | 23.38% |
2018 Q1 | -0.12 PLN | 14.29% |
2018 Q2 | -0.21 PLN | -75.0% |
2018 Q4 | -0.23 PLN | -9.52% |
2017 Q3 | 0.37 PLN | 0.0% |
2017 FY | - PLN | 4.94% |
2017 Q4 | -0.14 PLN | -137.84% |
2016 FY | - PLN | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Bioceltix S.A. | -3.49 PLN | -220.63% |
BIOTON S.A. | 0.03 PLN | 42326.415% |
Captor Therapeutics Spolka Akcyjna | -15.19 PLN | 26.333% |
Mabion S.A. | 2.55 PLN | 538.824% |
Molecure S.A. | -1.09 PLN | -926.606% |
NanoGroup S.A. | -0.39 PLN | -2769.231% |
Pharmena S.A. | 2.60 PLN | 530.385% |
Poltreg S.A. | -2.91 PLN | -284.536% |
Ryvu Therapeutics S.A. | -4.02 PLN | -178.358% |
Synthaverse S.A. | 0.07 PLN | 16628.804% |
Urteste S.A. | -4.32 PLN | -159.028% |